CytomX Therapeutics Total Assets 2014-2022 | CTMX
CytomX Therapeutics total assets from 2014 to 2022. Total assets can be defined as the sum of all assets on a company's balance sheet.
CytomX Therapeutics Annual Total Assets (Millions of US $) |
2021 |
$339 |
2020 |
$359 |
2019 |
$341 |
2018 |
$457 |
2017 |
$398 |
2016 |
$199 |
2015 |
$197 |
2014 |
$73 |
2013 |
$14 |
CytomX Therapeutics Quarterly Total Assets (Millions of US $) |
2022-09-30 |
$226 |
2022-06-30 |
$260 |
2022-03-31 |
$297 |
2021-12-31 |
$339 |
2021-09-30 |
$371 |
2021-06-30 |
$402 |
2021-03-31 |
$434 |
2020-12-31 |
$359 |
2020-09-30 |
$375 |
2020-06-30 |
$402 |
2020-03-31 |
$437 |
2019-12-31 |
$341 |
2019-09-30 |
$373 |
2019-06-30 |
$405 |
2019-03-31 |
$445 |
2018-12-31 |
$457 |
2018-09-30 |
$483 |
2018-06-30 |
$377 |
2018-03-31 |
$376 |
2017-12-31 |
$398 |
2017-09-30 |
$387 |
2017-06-30 |
$352 |
2017-03-31 |
$178 |
2016-12-31 |
$199 |
2016-09-30 |
$193 |
2016-06-30 |
$207 |
2016-03-31 |
$192 |
2015-12-31 |
$197 |
2015-09-30 |
$125 |
2015-06-30 |
$0 |
2015-03-31 |
$0 |
2014-12-31 |
$0 |
2014-09-30 |
$0 |
2013-12-31 |
$14 |
Sector |
Industry |
Market Cap |
Revenue |
Medical |
Medical - Biomedical and Genetics |
$0.177B |
$0.070B |
CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered in South San Francisco, California.
|